• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Psoriasis (PsO) - Articles and news items

psoriarsis

P is for Psoriasis

Blog, Z Homepage promo / 5 December 2016 / Niamh Louise Marriott, Digital Editor

P is for Psoriasis – the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research…

sb5

Samsung Bioepis seeks EU approval for its biosimilar adalimumab candidate, SB5

Industry news / 18 July 2016 / Victoria White, Digital Content Producer

At an estimated $4billion a year, the reference product, Humira, is among the European Union’s largest single drug expenditures…

fingernail psoriasis

AbbVie announces study data for Humira in fingernail psoriasis

Industry news / 7 July 2016 / Victoria White, Digital Content Producer

Nearly half of adult patients treated with Humira achieved at least a 75% improvement in their fingernail psoriasis compared to patients receiving placebo…

biosimilar etanercept

Sandoz announces EGALITY trial results for biosimilar etanercept

Industry news / 7 July 2016 / Victoria White, Digital Content Producer

The EGALITY study involved 531 patients and compared the efficacy and safety of biosimilar etanercept with the originator product, Enbrel…

leo pharma

AstraZeneca licenses skin disease drugs to LEO Pharma

Industry news / 1 July 2016 / Victoria White, Digital Content Producer

AstraZeneca has entered into an agreement with LEO Pharma for the global licence to tralokinumab in skin diseases.

psoriasis

Psoriasis survey reveals discrimination and low treatment expectations

Industry news / 29 June 2016 / Victoria White, Digital Content Producer

Findings from the largest global survey to date of people with psoriasis reveal 84% of people with moderate-to-severe psoriasis suffer discrimination…

enstilar

Enstilar launches in the UK for patients with plaque psoriasis

Industry news / 20 June 2016 / Victoria White, Digital Content Producer

Enstilar is the first fixed-combination, cutaneous foam spray for the once-daily topical treatment of all extents of plaque psoriasis…

flixabi

Infliximab biosimilar Flixabi approved in the EU

Industry news / 31 May 2016 / Victoria White, Digital Content Producer

The EC has granted marketing authorisation in the European Union (EU) for Flixabi, an infliximab biosimilar referencing Remicade…

taltz

Lilly’s psoriasis drug Taltz to generate sales over $1 billion by 2022

Industry news / 11 May 2016 / Victoria White, Digital Content Producer

Taltz is set to generate sales in excess of $1 billion in the US and EU due to its high clinical efficacy and good safety profile, according to GlobalData…

ixekizumab

EC grants marketing authorisation to Lilly’s ixekizumab

Industry news / 26 April 2016 / Victoria White, Digital Content Producer

The EC has granted marketing authorisation for Lilly’s ixekizumab (Taltz) for the treatment of moderate-to-severe plaque psoriasis in adults…

Psoriasis therapeutics market set to increase

GlobalData forecasts huge increase in psoriasis therapeutics market

Industry news / 13 April 2016 / Mandy Parrett, Editorial Assistant

The psoriasis therapeutics market is set to more than double from $6.6 billion in 2014 to over $13.3 billion by 2024, according to research and consulting firm GlobalData.

inflectra

FDA approves Inflectra (biosimilar infliximab) in the US

Industry news / 6 April 2016 / Victoria White, Digital Content Producer

With this approval, Celltrion’s Inflectra becomes the first biosimilar monoclonal antibody (mAb) medication to receive approval in the US…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +